Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Lung Neoplasms 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 18Cyclophosphamide 9fludarabine 8Nivolumab 8cemiplimab 5Carboplatin 5atezolizumab 4Gemcitabine 4Filgrastim 4Drug Therapy 4Docetaxel 4Cisplatin 4palbociclib 3durvalumab 3Paclitaxel 3Interleukin-2 3Bortezomib 3fludarabine phosphate 2epacadostat 2belinostat 2avelumab 2amminedichloro(2-methylpyridine)platinum(II) 2aldesleukin 2Tobacco Use Cessation Devices 2Temozolomide 2SS1(dsFv)PE38 2Riluzole 2Peripheral Blood Stem Cell Transplantation 2Oncolytic Virotherapy 2Ipilimumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Head and Neck Neoplasms × Canagliflozin × Gynecologic × Clear all
NCT04073680 2020-05-21

A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors

Petra Pharma

Phase 1/2 Unknown
60 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Colonic Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡